SK287832B6 - Use of acetyl L-carnitine in association with biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus. - Google Patents

Use of acetyl L-carnitine in association with biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus. Download PDF

Info

Publication number
SK287832B6
SK287832B6 SK1585-2003A SK15852003A SK287832B6 SK 287832 B6 SK287832 B6 SK 287832B6 SK 15852003 A SK15852003 A SK 15852003A SK 287832 B6 SK287832 B6 SK 287832B6
Authority
SK
Slovakia
Prior art keywords
carnitine
acetyl
biotin
insulin
acid
Prior art date
Application number
SK1585-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK15852003A3 (sk
Inventor
Menotti Calvani
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of SK15852003A3 publication Critical patent/SK15852003A3/sk
Publication of SK287832B6 publication Critical patent/SK287832B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1585-2003A 2001-05-29 2002-05-24 Use of acetyl L-carnitine in association with biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus. SK287832B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000294A ITRM20010294A1 (it) 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
PCT/IT2002/000338 WO2002096410A1 (en) 2001-05-29 2002-05-24 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus

Publications (2)

Publication Number Publication Date
SK15852003A3 SK15852003A3 (sk) 2004-04-06
SK287832B6 true SK287832B6 (sk) 2011-11-04

Family

ID=11455558

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1585-2003A SK287832B6 (sk) 2001-05-29 2002-05-24 Use of acetyl L-carnitine in association with biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus.

Country Status (18)

Country Link
US (2) US20040142879A1 (enExample)
EP (1) EP1399142B1 (enExample)
JP (1) JP4381685B2 (enExample)
KR (1) KR20040010666A (enExample)
AT (1) ATE333274T1 (enExample)
CA (1) CA2448244C (enExample)
CY (1) CY1105403T1 (enExample)
CZ (1) CZ297743B6 (enExample)
DE (1) DE60213237T2 (enExample)
DK (1) DK1399142T3 (enExample)
ES (1) ES2268053T3 (enExample)
HU (1) HUP0400060A2 (enExample)
IT (1) ITRM20010294A1 (enExample)
MX (1) MXPA03010921A (enExample)
PL (1) PL207522B1 (enExample)
PT (1) PT1399142E (enExample)
SK (1) SK287832B6 (enExample)
WO (1) WO2002096410A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230002B1 (en) * 2000-12-15 2015-04-28 Sigma Tau Ind Farmaceuti Use of l-carnitine for preparation of compositions for stabilizing the proteins
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US8569366B2 (en) 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
ES2546619T3 (es) * 2007-03-21 2015-09-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composición útil para la prevención de la diabetes tipo 2 y sus complicaciones en pacientes pre-diabéticos con resistencia a la insulina
GB201304112D0 (en) * 2013-03-07 2013-04-24 Univ Nottingham Modulation of energy expenditure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes

Also Published As

Publication number Publication date
DK1399142T3 (da) 2006-10-30
WO2002096410A1 (en) 2002-12-05
CZ20033221A3 (cs) 2004-06-16
KR20040010666A (ko) 2004-01-31
US20080269307A1 (en) 2008-10-30
ITRM20010294A0 (it) 2001-05-29
ITRM20010294A1 (it) 2002-11-29
MXPA03010921A (es) 2004-02-27
SK15852003A3 (sk) 2004-04-06
ES2268053T3 (es) 2007-03-16
CA2448244A1 (en) 2002-12-05
US20040142879A1 (en) 2004-07-22
PT1399142E (pt) 2006-10-31
EP1399142B1 (en) 2006-07-19
CY1105403T1 (el) 2010-04-28
PL207522B1 (pl) 2010-12-31
HUP0400060A2 (hu) 2004-04-28
JP4381685B2 (ja) 2009-12-09
EP1399142A1 (en) 2004-03-24
CZ297743B6 (cs) 2007-03-21
JP2004532866A (ja) 2004-10-28
DE60213237T2 (de) 2007-08-02
DE60213237D1 (de) 2006-08-31
CA2448244C (en) 2010-11-02
ATE333274T1 (de) 2006-08-15
US8053472B2 (en) 2011-11-08
PL367630A1 (en) 2005-03-07

Similar Documents

Publication Publication Date Title
US5157022A (en) Method for reducing blood cholesterol using arginine
US11911382B2 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US8053472B2 (en) Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
EP4331583A1 (en) Blood carnitine-increasing agent
EP1569635B1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
US20080161604A1 (en) Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
US8952059B2 (en) Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes
AU2007348123B2 (en) Composition useful for the treatment of type 2 diabetes
EP1547614B1 (en) Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
ES2425045T3 (es) Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
HK40044975A (en) Joint use of compound a and compound b in preparation of medications for treatment of gout or hyperuricemia
HK1135030B (en) Composition useful for the treatment of type 2 diabetes

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20130524